Show simple item record

dc.contributor.authorSharp, A
dc.contributor.authorBhosle, J
dc.contributor.authorAbdelraouf, F
dc.contributor.authorPopat, S
dc.contributor.authorO'Brien, M
dc.contributor.authorYap, TA
dc.date.accessioned2017-03-02T11:47:40Z
dc.date.issued2016-06
dc.identifier.citationEuropean journal of cancer (Oxford, England : 1990), 2016, 60 pp. 26 - 39
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/465
dc.identifier.eissn1879-0852
dc.identifier.doi10.1016/j.ejca.2016.03.004
dc.description.abstractSmall cell lung cancer (SCLC) is a smoking-induced malignancy with multiple toxin-associated mutations, which accounts for 15% of all lung cancers. It remains a clinical challenge with a rapid doubling time, early dissemination and poor prognosis. Despite multiple clinical trials in SCLC, platinum-based chemotherapy remains the mainstay of treatment in the first line advanced disease setting; good initial responses are nevertheless inevitably followed by disease relapse and survival ultimately remains poor. There are currently no molecularly targeted agents licenced for use in SCLC. Advances in sequencing the cancer genome and other high-throughput profiling technologies have identified aberrant pathways and mechanisms implicated in SCLC development and progression. Novel anti-tumour therapeutics that impact these putative targets are now being developed and investigated in SCLC. In this review, we discuss novel anti-tumour agents assessed in SCLC with reference to the complex molecular mechanisms implicated in SCLC development and progression. We focus on novel DNA damage response inhibitors, immune checkpoint modulators and antibody-drug conjugates that have shown promise in SCLC, and which may potentially transform treatment strategies in this disease. Finally, we envision the future management of SCLC and propose a biomarker-driven translational treatment paradigm for SCLC that incorporates next generation sequencing studies with patient tumours, circulating plasma DNA and functional imaging. Such modern strategies have the potential to transform the management and improve patient outcomes in SCLC.
dc.formatPrint-Electronic
dc.format.extent26 - 39
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectImmune System
dc.subjectHumans
dc.subjectLung Neoplasms
dc.subjectDNA Damage
dc.subjectAngiogenesis Inhibitors
dc.subjectAntineoplastic Agents
dc.subjectImmunotherapy
dc.subjectCell Communication
dc.subjectApoptosis
dc.subjectDNA Repair
dc.subjectSmall Cell Lung Carcinoma
dc.subjectDrug Discovery
dc.subjectMolecular Targeted Therapy
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectCell Cycle Checkpoints
dc.subjectPrecision Medicine
dc.titleDevelopment of molecularly targeted agents and immunotherapies in small cell lung cancer.
dc.typeJournal Article
dcterms.dateAccepted2016-03-02
rioxxterms.versionofrecord10.1016/j.ejca.2016.03.004
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean journal of cancer (Oxford, England : 1990)
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume60
pubs.embargo.termsNot known
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
icr.researchteamThoracic Oncologyen_US
icr.researchteamTranslational Therapeuticsen_US
icr.researchteamTreatment of thoracic tumoursen_US
dc.contributor.icrauthorSharp, Adamen
dc.contributor.icrauthorO'Brien, Maryen
dc.contributor.icrauthorYap, Timothyen
dc.contributor.icrauthorPopat, Sanjayen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record